����VR��Ƶ

9 May 2025, OSLO - ����VR��Ƶ and the Norwegian Institute of Public Health (NIPH) have bolstered the long-standing relationship between the two organizations by signing a Memorandum of Understanding (MoU) during a recent meeting between NIPH’s Director General Guri Rørtveit and ����VR��Ƶ’s CEO Richard Hatchett.

“In the current era of epidemic and pandemic risk, working together, building networks and sharing insights is key to the world’s ability to stop the next pandemic”, says ����VR��Ƶ’s CEO Richard Hatchett. “The Norwegian Institute of Public Health, with its wealth of technical expertise and its strong European and global connections, is a hugely valuable partner for ����VR��Ƶ. We are excited to collaborate with NIPH towards our shared goals of protecting the world from future epidemics and pandemics.”  

“We at the Norwegian Institute of Public Health are glad for the strengthened collaboration with ����VR��Ƶ. We have a common history with close collaboration in the shaping of ����VR��Ƶ, sharing offices, and most importantly, a huge interest in strengthening pandemic preparedness through global vaccine development, fair distribution and cooperation” says Guri Rørtveit, Director General of the Norwegian Institute of Public Health. 

Norway is one of ����VR��Ƶ’s founders, and the Coalition’s headquarters are based in Oslo. In its first few years of existence, ����VR��Ƶ was hosted by the NIPH which provided administrative and technical support as well as office space for the new organization. 

The strengthened partnership will reinforce the links between ����VR��Ƶ and European Union-wide vaccine coordination projects that NIPH is a member of. It will also facilitate the engagement of Norwegian institutions and networks in the global vaccine development and pandemic preparedness spheres.

The two organizations will share data and expertise and contribute to joint trainings for researchers and students in Norway. ����VR��Ƶ will support NIPH in its role as an advisor to the Norwegian Government regarding vaccines and monoclonal antibodies for outbreaks and pandemics. In addition, ����VR��Ƶ will facilitate collaboration between NIPH and ����VR��Ƶ-supported vaccine developers and networks to help strengthen vaccine development projects in the EU and Norway for the benefit of all.